Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Philogen S.p.A., now recruiting.
Overview
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT04443010 by Philogen S.p.A., with 226 participants planned, started 2021-01-20 and due to reach its primary completion in 2026-10. Interventions recorded: Onfekafusp alfa and Temozolomide.
Similar pages
not linked directly; found by shared links- TrialA Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Shares Philogen S.p.A., Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialA Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialPh I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialJK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialSonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Philogen S.p.A. and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Philogen S.p.A. and the tag pipeline.